Looking to Sell Your Hospice? Here Are 10 Things You Should Know About the 2026 Buyer Landscape

If you have been keeping an eye on the news lately, you know that the hospice world is moving fast. We are well into 2026, and the landscape for selling a hospice agency looks significantly different than it did just two years ago. For many owners, the stress of regulatory shifts and staffing shortages has led to a natural question: Is now the right time to exit?

At Senate Healthcare LLC, we are actively looking to acquire high-quality hospice agencies. We see the challenges you are facing because we are in the trenches of the market every day. Whether you are dealing with the transition to the new HOPE tool or trying to keep your head above water with the latest CMS rate adjustments, understanding how a buyer views your business is the key to a successful transition.

Quick-Scan Summary

Who this is for:

• Hospice owner-operators with annual revenues between $2M and $10M.

• Founders looking for a succession plan or a strategic partner to take the reins.

• Owners concerned about how new 2026 regulations affect their sale price.

Key Takeaways:

• Clinical compliance and staffing stability have replaced pure volume as the primary drivers of valuation multiples.

• The transition to the HOPE tool and the new SSVI scoring system are the "new frontier" for buyer due diligence.

• Geographic location matters more than ever, especially with increased scrutiny in fraud-heavy zones like Los Angeles.

The 2026 Market Context: Quality Over Quantity

The days of "growth at any cost" are largely behind us. In 2026, buyers are focused on the sustainability of your operations. While 2021 saw sky-high multiples driven by cheap capital, today’s buyers, including us at Senate Healthcare LLC, are more surgical. We are looking for agencies that have a clean clinical record and a team that actually wants to stay.

When we look at a potential acquisition, we are not just looking at your current patient census. We are looking at how ready you are for the "Transparency Era." With the public now having more access to hospice performance data than ever before, a "fixer-upper" agency is a much riskier bet for an acquirer.

1. The 2.6 Percent Reality and the New Cap

CMS has finalized the fiscal year 2026 wage index, resulting in a 2.6 percent increase in hospice payment rates. While any increase is welcome, it barely keeps pace with the rising costs of specialized labor and supplies. Additionally, the hospice aggregate cap for 2026 has been set at $35,361.44.

Buyers are looking closely at how close you are to this cap. If you are consistently bumping up against it, it signals a potential length-of-stay issue that could lead to a valuation "haircut" during the underwriting process. We look for agencies that manage their patient mix effectively to stay well within these limits.

2. The HOPE Tool is the New Gold Standard

Starting in October 2025, the industry transitioned from the old Hospice Item Set (HIS) to the Hospice Outcomes & Patient Evaluation (HOPE) tool. We are now seeing the first full year of data from this transition. Buyers are specifically looking for the 90 percent timeliness rule. If your staff is not completing these assessments on time, it creates a massive compliance red flag.

3. SSVI Transparency and the "Yelp" Effect

The new Hospice Scoring System (SSVI) is now public. This creates a transparency risk that did not exist a few years ago. Buyers will pull your SSVI scores before even signing an NDA. A low score suggests that your agency might struggle to attract referrals in a competitive market, which directly lowers the multiple a buyer is willing to pay.

4. Valuation Multiples: Platform vs. Add-on

It is helpful to look at benchmarks like the Enhabit deal, which saw a 10.2x EBITDA multiple for their platform. However, for most independent owners in the $2M to $10M revenue range, you should expect "add-on" multiples.

If your agency has $1M in EBITDA and you are operating as a clean, efficient add-on, a 5x multiple results in a $5M valuation. If you have "platform-like" qualities, such as a full middle-management tier, that multiple could climb higher.

5. Staffing Stability as an EBITDA Driver

In 2026, your nurse retention rate is a financial metric. When we evaluate an agency, we look at turnover. If we have to replace 40 percent of your staff post-acquisition, that is a massive hidden cost. Agencies with high retention command a premium because they represent lower operational risk.

6. The California and Los Angeles Fraud Crackdown

Geography is a major factor in 2026. If your agency is based in Los Angeles or certain parts of California, expect a much more rigorous audit during due diligence. Because of the heavy fraud crackdown in these areas, buyers are wary of "shell" agencies or those with unusual referral patterns. If you are in these zones, having a third-party clinical audit ready can significantly speed up a sale.

7. Clinical Compliance is No Longer Optional

We often see owners who have great financials but "messy" charts. In the current landscape, a buyer will likely hire a clinical firm to audit 50 to 100 of your charts. If they find a high percentage of technical errors, they will either walk away or demand a significant escrow holdback to cover potential future audits from CMS.

8. Technology and AI Documentation

Are you still using paper charts or a legacy EMR that does not support AI-assisted documentation? Buyers are looking for tech-enabled agencies. AI tools that help nurses finish documentation faster are a major plus because they directly impact staffing satisfaction and documentation accuracy.

9. Referral Diversification

If 80 percent of your referrals come from one single doctor or one skilled nursing facility, your business has high "concentration risk." If that doctor retires or that facility signs an exclusive deal with a competitor, your value evaporates overnight. We look for a healthy, diverse referral base.

10. The Succession Gap

Many owners are realizing they do not have a "Number 2" to take over. If you are the only one who knows how to run the business, you have "key-person dependence." To get the best price, you should spend the six months before a sale empowering a clinical director or office manager to handle daily operations without you.

Anonymized Owner Vignette: The Case of "Sarah"

Sarah owned a mid-sized hospice in a competitive suburban market. She was exhausted by the HOPE tool transition and the constant "90 percent timeliness" stress. Her financials were strong, but she was doing 60 hours a week herself.

When she approached a buyer, her valuation was initially lower than she expected because the buyer saw that the business could not function without her. By spending four months training a dedicated clinical manager and cleaning up her HOPE documentation workflows, she was able to show a "turnkey" operation. This simple shift increased her offer by nearly $800,000 because the buyer felt confident the agency would not collapse the day Sarah moved to Florida.

Plain-Language Glossary

• EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization. Basically, it is a measure of your agency's cash flow.

• Multiple: The number a buyer multiplies your EBITDA by to get your purchase price (e.g., $1M EBITDA x 5 Multiple = $5M Price).

• HOPE Tool: The new patient assessment system that replaced HIS in late 2025.

• SSVI: The Hospice Scoring System, which is a public-facing way for CMS to grade your quality.

• Holdback: A portion of the sale price kept in an account for a year or two to cover any unexpected legal or audit issues.

So what should you do now?

• Audit Your HOPE Compliance: Ensure your team is hitting that 90 percent timeliness mark consistently before you even think about listing.

• Review Your Payer Mix: Understand how the 2.6 percent rate increase affects your bottom line and where you can trim overhead.

• Identify Your "Key Person": If you are the only one holding the keys, start delegating now to reduce "founder risk."

• Get a Clean Financial Set: Ensure your books are professional and separate from any personal expenses.

At Senate Healthcare LLC, we understand that your hospice is more than just a business, it is a legacy of care. We are not brokers trying to sell your listing to the highest bidder; we are the buyers. We are looking for partners who want to ensure their patients and staff are taken care of long after the sale. If you are ready to explore what an exit could look like for your agency, we would love to have a confidential conversation.

Resources:

• https://www.cms.gov/medicare/enrollment-renewal/providers-suppliers/hospice-center

• https://www.cms.gov/medicare/quality/hospice/hope

• https://data.cms.gov/provider-data/topics/hospice-care

• https://www.mertztaggart.com/post/q1-2026-home-based-care-m-a-report

• https://www.stoneridgepartners.com/2026/02/25/2026-home-health-and-hospice-ma-outlook-multiples-trends-and-payer-risk/